Regional changes in sympathetic nerve activity and baroreceptor reflex function and arterial plasma levels of catecholamines, renin and vasopressin during naloxone-precipitated morphine withdrawal in rats.
The aim of the study was to examine regional changes in sympathetic nerve activity (SNA) and baroreceptor function and arterial plasma catecholamines, arginine vasopressin (AVP) and plasma renin activity during morphine withdrawal in chloralose-anesthetized rats. Dependence was induced by s.c. morphine base pellets. Adrenal, renal and splanchnic SNA and SNA from the lumbar sympathetic chain were recorded before and after i.v. injections of naloxone. Baroreceptor function was examined with phenylephrine-induced increases in mean arterial pressure. In separate experiments, arterial plasma norepinephrine, epinephrine, dopamine, plasma renin activity and AVP were measured before and after naloxone-precipitated withdrawal. Naloxone administration elicited an increase in mean arterial pressure and heart rate. Although renal SNA was inhibited by approximately 50%, adrenal SNA and lumbar SNA increased by approximately 400 and 80%, respectively. Splanchnic SNA did not change significantly. The baroreceptor-mediated inhibition of adrenal SNA was facilitated while that for renal SNA was attenuated. The arterial plasma level of norepinephrine was doubled and epinephrine increased almost 20-fold. AVP increased about 15-fold, whereas plasma renin activity showed only a minor increase after naloxone. This study shows that a marked differentiation of the SNA response occurs during morphine withdrawal in rats, which suggests an interaction between opioid receptors and the control of regional sympathetic output. Furthermore, large amounts of AVP and epinephrine are released, which probably contribute to the cardiovascular changes seen in the withdrawal phase.
Department of Physiology, University of Göteborg, Sweden.
M
M
Delle
S E
SE
Ricksten
J
J
Häggendal
K
K
Olsson
J O
JO
Skarphedinsson
P
P
Thorén
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002395:Catecholamines / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D009020:Morphine / Q000009:adverse effects*; D009270:Naloxone / Q000627:therapeutic use*; D010656:Phenylephrine / Q000494:pharmacology; D011311:Pressoreceptors / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012083:Renin / Q000097:blood*; D013153:Splanchnic Nerves / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000188:drug therapy*; D013564:Sympathetic Nervous System / Q000187:drug effects*; D014667:Vasopressins / Q000097:blood*
D002395:Catecholamines; D014667:Vasopressins; D010656:Phenylephrine; D009270:Naloxone; D009020:Morphine; D012083:Renin